Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Novartis scraps Fabhalta study in lupus nephritis

Novartis terminated a mid-stage trial of Fabhalta in lupus nephritis, citing “strategic considerations,” according to a federal clinical trials database. Fabhalta, also known as iptacopan, is a key part of Novartis' portfolio. It delivered $505 ...

We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.

Read the original at endpoints.news →

More in Health & Medicine

More from Friday 16 October →